

GLAXOSMITHKLINE PLC

Form 6-K

February 19, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 18 February 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Shares sold to meet tax liabilities

Following the vesting of awards granted in 2016 under the GlaxoSmithKline 2009 Performance Share Plan on 14 February 2019 and as notified on 15 February 2019, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities ('PDMRs') in Ordinary Shares and in American Depositary Shares ('ADSs') of the Company arising from the sale of Ordinary Shares or ADSs to meet tax liabilities.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
- b) Position/status Chief Executive Officer
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.8462	66,159

- d) Aggregated information n/a (single transaction)

- e) Date of the transaction 2019-02-15

- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status President, Global Vaccines
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
- | | | |
|-----------------------------|------------------------------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £15.8462 | 38,633 |
| d) Aggregated information | n/a (single transaction) | |
| e) Date of the transaction | 2019-02-15 | |
| f) Place of the transaction | London Stock Exchange (XLON) | |

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr J Ford
- b) Position/status SVP & General Counsel
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument GlaxoSmithKline plc
American Depositary Shares ('ADSs')

ISIN: US37733W1053

b) Nature of the transaction	The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	\$41.1716	2,311
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2019-02-15	
f) Place of the transaction	New York Stock Exchange (XNYS)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
------------------------------	--

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.8462	15,937
d) Aggregated information	n/a (single transaction)	

Aggregated volume Price
 e) Date of the transaction 2019-02-15
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 a) Name Mr B McNamara
 b) Position/status CEO, Consumer Healthcare
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument ('ADSs')
 GlaxoSmithKline plc
 American Depositary Shares
 ISIN: US37733W1053

b) Nature of the transaction
 The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

c) Price(s) and volume(s)
 Aggregated information
 Price(s) Volume(s)
 \$41.1716 16,675
 n/a (single transaction)

d) Aggregated volume Price
 e) Date of the transaction 2019-02-15
 f) Place of the transaction New York Stock Exchange
 (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
 a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer

- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
£15.8462 28,009
- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2019-02-15
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr R Simard
- b) Position/status President, Pharma Supply Chain
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.8462	3,873
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2019-02-15	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	SVP, Human Resources
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.	
------------------------------	--	--

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.8462	35,253
d) Aggregated information	n/a (single transaction)	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated volume Price
 e) Date of the transaction 2019-02-15
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson
 b) Position/status President, Global Affairs
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

c) Price(s) and volume(s)
 Price(s) Volume(s)
 £15.8462 20,283

d) Aggregated information n/a (single transaction)

Aggregated volume Price
 e) Date of the transaction 2019-02-15
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs V A Whyte
 b) Position/status Company Secretary

c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £15.8462 3,873
d) Aggregated information	n/a (single transaction)
e) Date of the transaction	2019-02-15
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 18, 2019

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc

